Ellis Investment Partners’s VanEck Pharmaceutical ETF PPH Stock Holding History

Ellis Investment Partners’s Portfolio PPH Stock Details PPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,466	Closed	-$314K	–	240
2024 Q1	$314K	Buy	+3,466	New	+$303K	0.07%	173
2022 Q4	–	Sell	-265	Closed	-$17K	–	596
2022 Q3	$17K	Hold	265	–	–	﹤0.01%	508
2022 Q2	$20K	Hold	265	–	–	0.01%	506
2022 Q1	$21K	Hold	265	–	–	0.01%	519
2021 Q4	$20K	Hold	265	–	–	﹤0.01%	537
2021 Q3	$19K	Hold	265	–	–	﹤0.01%	519
2021 Q2	$19K	Buy	265 +1	+0.4%	+$71	﹤0.01%	520
2021 Q1	$18K	Buy	264 +1	+0.4%	+$69	0.01%	508
2020 Q4	$18K	Buy	263 +1	+0.4%	+$64	0.01%	494
2020 Q3	$16K	Buy	262 +1	+0.4%	+$63	0.01%	499
2020 Q2	$16K	Buy	261 +2	+0.8%	+$121	0.01%	481
2020 Q1	$13K	Buy	259 +1	+0.4%	+$62	0.01%	450
2019 Q4	$16K	Buy	258 +1	+0.4%	+$60	0.01%	465
2019 Q3	$14K	Buy	257 +1	+0.4%	+$57	0.01%	494
2019 Q2	$15K	Buy	+256	New	+$14.8K	0.01%	478

Other funds holding PPH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Avalon Trust Santa Fe, New Mexico $1.45B AUM 35.31% 1-Year Est. Return

MIM

Miller Investment Management West Conshohocken, Pennsylvania $1.01B AUM 13.96% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCIA

Prime Capital Investment Advisors Overland Park, Kansas $8.65B AUM 19.52% 1-Year Est. Return

FPGK

Financial Partners Group (Kansas) Overland Park, Kansas $836M AUM 21.04% 1-Year Est. Return

Ellis Investment Partners's PPH Position: Q2 2024 in Review

Ellis Investment Partners sold out of VanEck Pharmaceutical ETF (PPH) in Q2 2024, closing a stake of 3,466 shares — an estimated $314K sold.

Ellis Investment Partners first reported a position in PPH in Q2 2019 and held it in 15 quarters. The position peaked at $314K in Q1 2024. 140 funds tracked by Wall St. Rank hold PPH as of Q2 2024.

Ellis Investment Partners reported no remaining VanEck Pharmaceutical ETF position as of Q2 2024 after selling out during the quarter.
Ellis Investment Partners sold 3,466 VanEck Pharmaceutical ETF shares in Q2 2024, an estimated $314K.
Ellis Investment Partners first reported a position in VanEck Pharmaceutical ETF in Q2 2019 and held it in 15 quarters.
Ellis Investment Partners's VanEck Pharmaceutical ETF position peaked at $314K in Q1 2024.
140 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2024.

Based on Ellis Investment Partners's 13F filing for Q2 2024, filed 6 Aug 2024.